Theseus Pharmaceuticals I... (THRX)
4.07
0.01 (0.25%)
At close: Feb 13, 2024, 8:59 PM
0.25% (1D)
| Bid | n/a |
| Market Cap | 181.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.86M |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -3.033582089552239 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 677,694 |
| Avg. Volume (20D) | 849,600 |
| Open | 4.06 |
| Previous Close | 4.06 |
| Day's Range | 4.06 - 4.07 |
| 52-Week Range | 2.05 - 12.37 |
| Beta | 3.98 |
About THRX
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes re...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 2021
Employees 38
Stock Exchange NASDAQ
Ticker Symbol THRX
Website https://theseusrx.com